ORG Wealth Partners LLC Sells 363 Shares of Becton, Dickinson and Company (NYSE:BDX)

ORG Wealth Partners LLC lessened its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 36.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 633 shares of the medical instruments supplier’s stock after selling 363 shares during the quarter. ORG Wealth Partners LLC’s holdings in Becton, Dickinson and Company were worth $144,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in BDX. Livelsberger Financial Advisory acquired a new position in shares of Becton, Dickinson and Company during the 3rd quarter worth about $26,000. Ashton Thomas Securities LLC acquired a new position in shares of Becton, Dickinson and Company during the 3rd quarter worth about $33,000. Tompkins Financial Corp lifted its position in shares of Becton, Dickinson and Company by 44.2% during the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 46 shares during the last quarter. Sound Income Strategies LLC lifted its position in shares of Becton, Dickinson and Company by 35.8% during the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 44 shares during the last quarter. Finally, Kennebec Savings Bank acquired a new position in shares of Becton, Dickinson and Company during the 3rd quarter worth about $46,000. Institutional investors own 86.97% of the company’s stock.

Analyst Upgrades and Downgrades

BDX has been the subject of several recent research reports. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their price target for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. StockNews.com cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Finally, Evercore ISI increased their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $283.50.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Shana Carol Neal sold 788 shares of the firm’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $235.00, for a total value of $185,180.00. Following the transaction, the executive vice president now directly owns 16,201 shares in the company, valued at $3,807,235. This trade represents a 4.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Roland Goette sold 638 shares of the firm’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $219.03, for a total value of $139,741.14. Following the completion of the transaction, the executive vice president now owns 14,217 shares in the company, valued at $3,113,949.51. This represents a 4.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 8,747 shares of company stock worth $1,949,520. Insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Stock Down 0.3 %

NYSE BDX opened at $233.65 on Friday. The firm has a market cap of $67.76 billion, a PE ratio of 39.34, a price-to-earnings-growth ratio of 1.64 and a beta of 0.39. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.17 and a quick ratio of 0.74. The stock’s 50 day simple moving average is $226.91 and its 200 day simple moving average is $232.45. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $248.42.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, beating analysts’ consensus estimates of $3.77 by $0.04. The firm had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The business’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same period last year, the company earned $3.42 EPS. As a group, sell-side analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th were given a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 1.78%. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. The ex-dividend date was Monday, December 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 70.03%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.